A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants
A Phase 1, Randomized, Double-Masked, Placebo-Controlled, Single-Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CITY-RBP4 Administered Subcutaneously in Healthy Volunteers and Participants With Stargardt Disease Type 1 (STGD1)
This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following single-ascending doses and multiple doses, via subcutaneous (SC) administration.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
The study consists of 3 sequential parts:
- Part A: Single-ascending doses in healthy volunteers
- Part B: Single-ascending doses in participants with Stargardt Disease Type 1 (STGD1)
- Part C: Multiple doses in participants with Stargardt Disease Type 1 (STGD1)
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: City Therapeutics
- Telefonnummer: 857-219-5440
- E-Mail: clinicaltrials@citytx.com
Studienorte
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Rekrutierung
- Nucleus Network
-
Kontakt:
- Nucleus Network Melbourne
- Telefonnummer: +61-1800-243-733
- E-Mail: melbourne@nucleusnetwork.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria (Part A):
- Willing and able to provide written informed consent form
- Be aged 18 to 45 years (inclusive) at the time of signing the informed consent form
- Generally healthy on medical history, exam, labs, and ECG
- BCVA 20/25 or better in each eye
- Serum retinol above protocol threshold
- Body weight ≥40 kg and BMI of 18.0 to 32.0 kg/m2
- Men and WOCBP must agree to use highly effective methods of contraception or practice abstinence from 30 days before the first dose of CITY-RBP4, throughout the study, and for at least 180 days after treatment with CITY-RBP4 or the last study visit, whichever is longer; men must refrain from donating or banking sperm during the same period
- Female participants who are not WOCBP should meet at least 1 of the following criteria: have undergone a documented hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy; have medically confirmed ovarian failure, or achieved postmenopausal status
Key Exclusion Criteria (Part A):
- Clinically significant ocular disease or prior ocular surgery that could interfere with safety assessments
- History of vitamin A deficiency, malabsorption, or chronic diarrhea
- Clinically significant cardiac, hepatic, renal, pulmonary, neurologic, or psychiatric disease
- Positive hepatitis B, hepatitis C, or HIV screening
- Prior RNAi/oligonucleotide therapy or recent investigational treatment
- Recent vitamin A-related supplements, retinoids, or medications affecting vitamin A metabolism
- Pregnancy or breastfeeding, if applicable
Key Inclusion Criteria (Parts B and C)
- Participants aged 12 to 45 years
- Clinical diagnosis of STGD1 with documented ABCA4 pathogenic/likely pathogenic variant
- Minimum BCVA is required in the study eye
- Subjects must have a defined aggregate atrophic lesion in 1 or both eyes
- Body weight ≥40 kg
- Able to complete key ophthalmic safety assessments and comply with study precautions
Key Exclusion Criteria (Parts B and C)
- Ocular conditions that could confound retinal imaging or safety evaluation
- Prior ocular gene therapy, stem cell therapy, or retinal implant
- Vitamin A deficiency or recent prohibited vitamin A-related treatments
- Recent interventional study participation
- Clinically significant non-ophthalmic disease, abnormal screening labs/ECG, or positive hepatitis B, hepatitis C, or HIV screening
- Pregnancy or breastfeeding, if applicable
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Placebo-Komparator: Bei gesunden Erwachsenen (Teil A)
|
Saline (subcutaneous injection) |
|
Experimental: CITY-RBP4 in Healthy Adults (Part A)
|
siRNA (subcutaneous injection) |
|
Experimental: CITY-RBP4 in Participants with STGD1 (Parts B & C)
|
siRNA (subcutaneous injection) |
|
Placebo-Komparator: In Participants with STGD1 (Parts B & C)
|
Saline (subcutaneous injection) |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence, severity, and relationship of treatment-emergent adverse events (TEAEs)
Zeitfenster: Through study completion, up to Day 360
|
To evaluate the safety and tolerability of single and multiple doses of CITY-RBP4 in healthy adults and participants with Stargardt disease Type 1 (STGD1) |
Through study completion, up to Day 360
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Plasma concentrations of CITY-RBP4
Zeitfenster: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Urine concentrations of CITY-RBP4
Zeitfenster: Part A and B only: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after a single dose of CITY-RBP4 in healthy adults and participants with STGD1 |
Part A and B only: Day 1 to Day 2
|
|
Maximum plasma concentration (Cmax)
Zeitfenster: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Time to maximum plasma concentration (Tmax)
Zeitfenster: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Area under plasma concentration-time curve (AUC)
Zeitfenster: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Terminal elimination half-life (t1/2)
Zeitfenster: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Apparent clearance (CL/F)
Zeitfenster: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Amount excreted unchanged (Ae)
Zeitfenster: Part A and B only: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after a single dose of CITY-RBP4 in healthy adults and participants with STGD1 |
Part A and B only: Day 1 to Day 2
|
|
Change from baseline in plasma RBP4 concentrations
Zeitfenster: Up to Day 360
|
evaluate the pharmacodynamic (PD) effects of CITY-RBP4 on plasma retinol-binding protein 4 (RBP4) levels after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Up to Day 360
|
|
Change from baseline in serum retinol concentrations
Zeitfenster: Up to Day 360
|
To evaluate the pharmacodynamic (PD) effects of CITY-RBP4 on serum retinol levels after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Up to Day 360
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Medical Director, City Therapeutics
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- CITY-RBP4-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .